Skip to main content
Premium Trial:

Request an Annual Quote

Norak to Screen Against GPCRs for BASF; Extends Agreement with Lundbeck

NEW YORK, Aug. 16 (GenomeWeb News) - Norak Bioscience will use its Transfluor fluorescence cell-based assay technology to discover compounds that act against G protein-coupled receptor targets developed by BASF, Norak said.

 

Under the terms of the agreement, Norak, based in Research Triangle Park, NC, will use Transfluor to screen a selected portion of its larger compound library against GPCR targets provided by BASF, which is interested in optimizing and developing compounds for crop protection products, Norak said.

 

Financial terms of the deal were not disclosed; however, Norak said it will receive technology access and screening fees, as well as milestones and royalties.

 

Norak also announced that Lundbeck A/S has exercised its option to screen another of its GPCR targets of interest using Transfluor. The option was part of a screening collaboration agreement signed in December 2002, which stated that Norak would develop a Transfluor cell line expressing the GPCR target of interest for Lundbeck, and then screen the cell line at Norak using its high-throughput imaging systems and against a compound library of Lundbeck's choice.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.